Cusumano Giacomo, Paternò Daniele Salvatore, Terminella Alberto, Sorbello Massimiliano, La Via Luigi
University Hospital Policlinico "G. Rodolico - San Marco", Via S. Sofia 78, 95123, Catania, Italy.
Department of General Surgery and Medical-Surgical Specialties, University of Catania, Catania, Italy.
Updates Surg. 2025 Jun 5. doi: 10.1007/s13304-025-02234-w.
Acquired benign tracheal stenosis represents a challenging condition characterized by narrowing of the tracheal lumen, with post-intubation and post-tracheostomy stenosis accounting for approximately 90% of acquired cases. This comprehensive review examines current treatment strategies, from conservative management to surgical reconstruction, highlighting their indications, limitations, and outcomes based on recent clinical evidence. Conservative management, including humidification, corticosteroid therapy, and treatment of underlying conditions, plays a crucial role in selected cases with mild stenosis. Endoscopic techniques, such as dilation, laser treatment, and airway stenting, offer minimally invasive options with success rates varying from 40 to 80%, depending on patient selection. Surgical approaches, including tracheal resection with primary anastomosis and laryngotracheal reconstruction, remain the gold standard for definitive treatment, with success rates exceeding 90% in specialized centers. The choice of treatment modality depends on various factors, including stenosis length, location, severity, and patient characteristics. Emerging treatments, including tracheal replacement, bioengineered tracheal replacements, three-dimensional printing technology, and cell therapy approaches, show promise in addressing the limitations of traditional techniques, though long-term data remains limited. The integration of various biotechnology approaches has led to the development of hybrid solutions, combining 3D-printed scaffolds with cellular components and growth factors. However, significant challenges remain in the translation of these technologies to clinical practice, including issues of vascularization, immune response, and long-term stability. This review provides an up-to-date analysis of available treatment options and future directions in tracheal stenosis management.
获得性良性气管狭窄是一种具有挑战性的病症,其特征为气管腔狭窄,其中插管后和气管切开术后狭窄约占获得性病例的90%。本综述探讨了从保守治疗到手术重建的当前治疗策略,根据近期临床证据强调了它们的适应症、局限性和治疗效果。保守治疗,包括加湿、皮质类固醇治疗和基础疾病的治疗,在轻度狭窄的特定病例中起着关键作用。内镜技术,如扩张、激光治疗和气道支架置入,提供了微创选择,成功率根据患者选择在40%至80%之间。手术方法,包括气管切除一期吻合术和喉气管重建术,仍然是确定性治疗的金标准,在专业中心成功率超过90%。治疗方式的选择取决于多种因素,包括狭窄长度、位置、严重程度和患者特征。新兴治疗方法,包括气管置换、生物工程气管置换、三维打印技术和细胞治疗方法,在解决传统技术的局限性方面显示出前景,尽管长期数据仍然有限。各种生物技术方法的整合导致了混合解决方案的发展,将3D打印支架与细胞成分和生长因子相结合。然而,将这些技术转化为临床实践仍面临重大挑战,包括血管化、免疫反应和长期稳定性等问题。本综述对气管狭窄管理中可用的治疗选择和未来方向进行了最新分析。